1-Ethyl-4-(8-chlor-5,6-dihydro-11H-benzo-<5,6>-cyclohepta-<1,2-b>-pyridin-11-ylidin)-piperidin

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并环庚烷吡啶
• 英文名称: 1-Ethyl-4-(8-chlor-5,6-dihydro-11H-benzo-<5,6>-cyclohepta-<1,2-b>-pyridin-11-ylidin)-piperidin
• 英文别名: 8-chloro-11-(1-ethylpiperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine；VUF16144；13-Chloro-2-(1-ethylpiperidin-4-ylidene)-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene
• 化学式: C₂₁H₂₃ClN₂
• 分子量: 338.88
• InChiKey: HCTNSTBDADQMJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  溴乙烷 、 地氯雷他定 在 sodium carbonate 作用下， 以 甲苯 为溶剂， 反应 3.0h， 以55%的产率得到1-Ethyl-4-(8-chlor-5,6-dihydro-11H-benzo-<5,6>-cyclohepta-<1,2-b>-pyridin-11-ylidin)-piperidin
  参考文献：
  名称：

  Zhong; Blume, Pharmazie, 1994, vol. 49, # 10, p. 736 - 739

  摘要：

  DOI：

文献信息

• Route to Prolonged Residence Time at the Histamine H₁ Receptor: Growing from Desloratadine to Rupatadine
  作者：Reggie Bosma、Zhiyong Wang、Albert J. Kooistra、Nick Bushby、Sebastiaan Kuhne、Jelle van den Bor、Michael J. Waring、Chris de Graaf、Iwan J. de Esch、Henry F. Vischer、Robert J. Sheppard、Maikel Wijtmans、Rob Leurs

  DOI：10.1021/acs.jmedchem.9b00447

  日期：2019.7.25

  Drug-target binding kinetics are an important predictor of in vivo drug efficacy, yet the relationship between ligand structures and their binding kinetics is often poorly understood. We show that both rupatadine (1) and desloratadine (2) have a long residence time at the histamine H-1 receptor (H1R). Through development of a [H-3]levocetirizine radiolabel, we find that the residence time of 1 exceeds that of 2 more than 10-fold. This was further explored with 22 synthesized rupatadine and desloratadine analogues. Methylene-linked cycloaliphatic or beta-branched substitutions of desloratadine increase the residence time at the H1R, conveying a longer duration of receptor antagonism. However, cycloaliphatic substituents directly attached to the piperidine amine (i.e., lacking the spacer) have decreased binding affinity and residence time compared to their methylene-linked structural analogues. Guided by docking studies, steric constraints within the binding pocket are hypothesized to explain the observed differences in affinity and binding kinetics between analogues.
• NOVEL P450-BM3 VARIANTS WITH IMPROVED ACTIVITY
  申请人：Codexis, Inc.

  公开号：EP3319987B1

  公开（公告）日：2021-05-05
• Compounds that inhibit cholinesterase
  申请人：Rupniak Nadia M. J.

  公开号：US20080261950A1

  公开（公告）日：2008-10-23

  Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The compounds of the invention are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the compound can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.
• US8101782B2
  申请人：——

  公开号：US8101782B2

  公开（公告）日：2012-01-24
• Zhong; Blume, Pharmazie, 1994, vol. 49, # 10, p. 736 - 739
  作者：Zhong、Blume

  DOI：——

  日期：——